Table 2 Univariate and multivariate cox regression analyses for overall survival in patients with gastric cancer.

From: Comparing prognostic value of preoperative platelet indexes in patients with resectable gastric cancer

Variables

Univariate analysis

Multivariate analysis

HR (95%CI)

P value

HR (95%CI)

P value

Primary cohort

Sex: male vs. female

0.92 (0.71–1.18)

0.507

  

Age: > 60 vs. ≤ 60

1.18 (0.91–1.53)

0.204

  

Tumor location

 

0.002*

 

0.077

 Middle vs. upper

0.70 (0.51–0.97)

0.029*

0.75 (0.51–1.14)

0.213

 Lower vs. upper

0.57 (0.42–0.78)

< 0.001*

0.69 (0.50–0.95)

0.024*

Grade: poorly vs. well

2.16 (1.70–2.76)

< 0.001*

1.33 (0.97–1.68)

0.071

Lauren type

 

0.947

  

 Intestinal vs. diffuse

1.04 (0.74–1.48)

0.820

  

 Mixed vs. diffuse

1.00 (0.70–1.43)

0.997

  

Tumor size: > 5 vs. ≤ 5

2.20 (1.70–2.84)

< 0.001*

1.76 (1.36–2.28)

< 0.001*

Lymphovascular: yes vs. no

1.05 (0.81–1.37)

0.703

  

Perineural: yes vs. no

1.78 (1.41–2.26)

< 0.001*

1.19 (0.81–1.59)

0.173

TNM stage

 

< 0.001*

 

< 0.001*

 II vs. I

2.15 (1.39–3.32)

0.001*

1.73 (1.11–2.70)

0.015*

 III vs. I

5.66 (3.82–8.40)

< 0.001*

3.77 (2.48–5.73)

< 0.001*

Chemotherapy: yes vs. no

1.14 (0.90–1.45)

0.285

  

MPV/PC: > 0.036 vs. ≤ 0.036

0.47 (0.37–0.60)

< 0.001*

0.61 (0.47–0.78)

< 0.001*

NLR: > 1.35 vs. ≤ 1.35

1.66 (1.30–2.11)

< 0.001*

1.25 (0.97–1.60)

0.088

PLR: > 132 vs. ≤ 132

1.83 (1.40–2.39)

< 0.001*

1.24 (0.94–1.64)

0.130

SII: > 315 vs. ≤ 315

1.89 (1.49–2.40)

< 0.001*

1.22 (0.95–1.57)

0.123

CNPS

 

< 0.001*

 

0.202

 1 vs. 0

2.10 (1.47–2.99)

< 0.001*

1.39 (0.97–2.00)

0.074

 2 vs. 0

2.47 (1.76–3.47)

< 0.001*

1.29 (0.89–1.86)

0.178

Validation cohort

Sex: male vs. female

0.99 (0.62–1.60)

0.977

  

Age: > 60 vs. ≤ 60

1.27 (1.01–1.58)

0.039

  

Tumor location

 

0.752

  

 Middle vs. upper

0.91 (0.44–1.87)

0.798

  

 Lower vs. upper

1.09 (0.55–2.14)

0.810

  

Grade: poorly vs. well

1.18 (0.96–1.45)

0.121

  

Lauren type

 

0.794

  

 Intestinal vs. diffuse

1.17 (0.63–2.16)

0.625

  

 Mixed vs. diffuse

1.24 (0.67–2.30)

0.497

  

Tumor size: > 5 vs. ≤ 5

2.22 (1.68–2.94)

< 0.001*

1.89 (1.42–2.53)

< 0.001*

Lymphovascular: yes vs. no

1.34 (0.86–2.11)

0.201

  

Perineural: yes vs. no

1.28 (0.79–2.05)

0.315

  

TNM stage

 

< 0.001*

 

< 0.001*

 II vs. I

2.90 (1.53–5.49)

0.001*

2.21 (1.16–4.22)

0.017*

 III vs. I

6.19 (3.16–12.13)

< 0.001*

4.44 (2.45–8.79)

< 0.001*

Chemotherapy: yes vs. no

1.30 (0.84–2.00)

0.240

  

MPV/PC: > 0.036 vs. ≤ 0.036

0.34 (0.22–0.52)

< 0.001*

0.43 (0.28–0.67)

< 0.001*

NLR: > 1.35 vs. ≤ 1.35

2.35 (1.40–3.96)

0.001*

1.78 (0.99–3.22)

0.055

PLR: > 132 vs. ≤ 132

1.77 (1.16–2.70)

0.008*

1.62 (0.89–2.73)

0.121

SII: > 315 vs. ≤ 315

2.22 (1.45–3.38)

< 0.001*

1.56 (0.99–2.43)

0.051

CNPS

 

0.003*

 

0.076

 1 vs. 0

1.75 (0.92–3.32)

0.087

1.47 (0.73–2.93)

0.278

 2 vs. 0

2.59 (1.47–4.57)

0.001*

2.00 (1.07–3.75)

0.030*

  1. TNM tumor, node, metastasis, AJCC American Joint Committee on Cancer, MPV/PC mean platelet volume to platelet count, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio, CNPS combined neutrophil-platelet score, SII systemic immune-inflammation index. *Represents a statistically difference.
Back to article page